Chief Financial Officer, Juvenescence
The aspiration is to take the moonshot, the passion is to inspire greater interest in healthspan not just in the scientific community, but with the public.
David Ellam, the Chief Financial Officer of Juvenescence, is a Chartered Accountant (ACA) with extensive experience in both the US and UK in private and listed biotech companies.
David was attracted to Juvenescence because it isn’t like a traditional regular biotech company.
“The aspiration is to take the moonshot,” he says, “the passion is to inspire greater interest in healthspan not just in the scientific community, but with the public.”
David was CFO and Board member at AIM-listed Silence Therapeutics Plc in London, as well as the EUMEA Finance Lead for BioMarin Pharmaceutical Inc. as the EUMEA business grew from 50+ to 500+ people. His finance team supported the startup of manufacturing in Ireland, the expansion of commercial activities, post-acquisition integration activities and system implementations.
David has a BA in English & Philosophy from the University of Birmingham in the UK.
David can be found in the gym working out several times a week. He and his wife are fully committed to physical fitness.